Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden

OBJECTIVE: The aim was to estimate the cost-effectiveness of inotuzumab ozogamicin (InO) versus standard of care chemotherapy (SoC) for adults with relapsed or refractory B cell acute lymphoblastic leukaemia (R/R ALL) in Sweden and Norway, and compare this to evaluations made by the health technolog...

Descripción completa

Detalles Bibliográficos
Autores principales: van Oostrum, I., Russell-Smith, T. A., Jakobsson, M., Torup Østby, J., Heeg, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807767/
https://www.ncbi.nlm.nih.gov/pubmed/34309818
http://dx.doi.org/10.1007/s41669-021-00287-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807767/
https://www.ncbi.nlm.nih.gov/pubmed/34309818
http://dx.doi.org/10.1007/s41669-021-00287-2

Ejemplares similares